P341 Faecal biomarkers compared with MRI using the MaRIA and Clermont scores for monitoring inflammatory activity in patients with Crohn's disease. (16th January 2018)

• Record Type: Journal Article
• Authors: Langhorst, J; Koch, A; Boone, J; Rueffer, A; Dobos, G; Umutlu, L; Li, Y
• Is Part Of: Journal of Crohn's and colitis. Volume 12:Number 1(2018:Jan.)Supplement 1
• Page Start: S274
• Page End: S275
• Publication Date: 2018-01-16
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjx180.468
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Fecal biomarkers like calprotectin (CAL) and lactoferrin (LF) have been evaluated regarding their capacity to differentiate and monitor disease activity in inflammatory bowel disease (IBD). These non-invasive biomarkers are increasingly popular and used in all-day patient care. Magnetic resonance imaging (MRI) is the gold standard approach to diagnose and monitor small bowel Crohn's disease (CD). Magnetic Resonance Index of Activity (MaRIA) and the Clermont score are validated MRI activity indices in grading activity and severity of inflammation in patients with CD. The aim was to evaluate the performance of fecal biomarkers compared with the MaRIA and Clermont score in patients with CD. Methods: Fecal samples were collected to determine LF, CAL, PMN-elastasis (PMN-e), S100 calcium-binding protein A12 (S100A12), and eosinophil-derived neurotoxin (EDN) by enzyme immunoassay (EIA) and results are reported as µg/g. In every patient, an MRI was performed and MaRIA and the Clermont score were calculated and standard cut-offs were applied by two independent experienced radiologists. Receiver operating characteristic (ROC) curves for each fecal biomarker using MaRIA and Clermont score as reference standard were calculated to determine sensitivity, specificity, and accuracy using optimised cut-offs. Results: A total of 50 patients with CD were included in the study. Sociodemographic and clinical characteristics are shown in Table 1. According the MaRia score n = 41 patients and according to the Clermont score n = 42 patients showed signs of active inflammation. Mean levels for patients with active/inactive inflammation were 12.43 (µg/g)/1.90 (µg/g) in LF, 224.86/ (µg/g) 151.17 (µg/g) in CAL, 0.17 (µg/g)/0.09 (µg/g) in PMN-e, 64.91 (µg/g)/79.09 (µg/g) in S100A12 and 1.4 (µg/g)/0.47 (µg/g) in EDN. Using optimised cut-offs, EDN, LF, and CAL were able to distinguish between active and inactive CD (see Table 2). Conclusions: Fecal Lactoferrin, Calprotectin, and EDN were significantly correlated to the Clermont score; however, only Lactoferrin was correlated to the MaRIA score. These results support the utility of fecal biomarkers for detecting active inflammation in patients with Crohn's disease.